Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine

Bibliography

• Vocci FJ, Acri J, Elkashef A. Medication development for addictive disorders: the state of the science. Am J Psychiatry 2005;162:1432-40
   PubMed Web of Science ®Google Scholar
• Dole VP, Nyswander MK, Kreek MJ. Narcotic blockade. Arch Intern Med 1966;118:304-9
   PubMed Web of Science ®Google Scholar
• Deamer RL, Wilson DR, Clark DS, Torsades de Pointes associated with high dose levomethadyl acetate (ORLAAM®). J Addict Dis 2001;20:7-14
   PubMed Web of Science ®Google Scholar
• Resnick RB. Food and Drug Administration approval of buprenorphine-naloxone for office treatment of addiction. Ann Int Med 2003;138:360
   PubMed Web of Science ®Google Scholar
• Cowan A, Lewis JW, MacFarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 1977;60:537-45
   PubMed Web of Science ®Google Scholar
• Walsh SL, Preston KL, Stitzer ML, Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994;55:569-80
   PubMed Web of Science ®Google Scholar
• Johnson RE, Chutuape MA, Strain EC, A comparison of levomethadol acetate, buprenorphine and methadone for opioid dependence. N Engl J Med 2000;343:1290-7
   PubMed Web of Science ®Google Scholar
• Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis 2012;31:207-25
   PubMed Web of Science ®Google Scholar
• Tetrault JM, Fiellin DA. Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals. Drugs 2012;72:217-28
   PubMed Web of Science ®Google Scholar
• Soyka M, Apelt SM, Lieb M, One-year mortality rates of patients receiving methadone and buprenorphine maintenance therapy: a nationally representative cohort study in 2694 patients. J Clin Psychopharmacol 2006;26:657-60
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Abdi S, Atluri S, American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part I–evidence assessment. Pain Physician 2012;15:S1-65
   Google Scholar
• Manchikanti L, Abdi S, Atluri S, American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2–guidance. Pain Physician 2012;15:S67-116
   PubMed Web of Science ®Google Scholar
• Rosenblum A, Cruciani RA, Strain EC, Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol. J Opioid Manag 2012;8:369-82
   PubMedGoogle Scholar
• Hernandez SH, Nelson LS. Prescription drug abuse: insight into the epidemic. Clin Pharmacol Ther 2010;88:307-17
   PubMed Web of Science ®Google Scholar
• Maxwell JC, McCance-Katz EF. Indicators of buprenorphine and methadone use and abuse: what do we know? Am J Addict 2010;19:73-88
   PubMed Web of Science ®Google Scholar
• CDC. Vital signs: risk for overdose from methadone used for pain relief - United States, 1999-2010. MMWR Morb Mortal Wkly Rep 2012;61:493-7
   PubMedGoogle Scholar
• Johanson CE, Arfken CL, di Menza S, Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. Drug Alcohol Depend 2012;120:190-5
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Helm S II, Fellows B, Opioid epidemic in the United States. Pain Physician 2012;15:ES9-38
   PubMed Web of Science ®Google Scholar
• Kuehn BM. Methadone overdose deaths rise with increased prescribing for pain. J Am Med Assoc 2012;308:749-50
   PubMed Web of Science ®Google Scholar
• Litovitz TL, Klein-Schwartz W, White S, 2000; Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2001;19:337-95
   Web of Science ®Google Scholar
• Litovitz TL, Klein-Schwartz W, Rodgers GC Jr, 2001 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2002;20:391-452
   PubMed Web of Science ®Google Scholar
• Watson WA, Litovitz TL, Rodgers GC Jr, 2002 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003;21:353-421
   PubMed Web of Science ®Google Scholar
• Watson WA, Litovitz TL, Klein-Schwartz W, 2003 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2004;22:335-404
   PubMed Web of Science ®Google Scholar
• Watson WA, Litovitz TL, Rodgers GC Jr, 2004 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2005;23:589-666
   PubMed Web of Science ®Google Scholar
• Lai MW, Klein-Schwartz W, Rodgers GC, 2005 Annual Report of the American Association of Poison Control Centers' national poisoning and exposure database. Clin Toxicol (Phila) 2006;44:803-932
   PubMed Web of Science ®Google Scholar
• Bronstein AC, Spyker DA, Cantilena LR Jr, 2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS). Clin Toxicol (Phila) 2007;45:815-917
   PubMed Web of Science ®Google Scholar
• Bronstein AC, Spyker DA, Cantilena LR Jr, 2007 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report. Clin Toxicol (Phila) 2008;46:927-1057
   PubMed Web of Science ®Google Scholar
• Bronstein AC, Spyker DA, Cantilena LR Jr, 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila) 2009;47:911-1084
   PubMed Web of Science ®Google Scholar
• Bronstein AC, Spyker DA, Cantilena LR Jr, 2009 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 27th Annual Report. Clin Toxicol (Phila) 2010;48:979-1178
   PubMed Web of Science ®Google Scholar
• Bronstein AC, Spyker DA, Cantilena LR Jr, 2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol (Phila) 2011;49:910-41
   PubMed Web of Science ®Google Scholar
• SAMHSA. Drug abuse warning network, 2006: national estimates of drug-related emergency department visits. Substance Abuse and Mental Health Services Administration, Rockville, MD; 2008
   Google Scholar
• SAMHSA. Drug abuse warning network, 2007: national estimates of drug-related emergency department visits. Substance Abuse and Mental Health Services Administration, Rockville, MD; 2010
   Google Scholar
• SAMHSA. Drug abuse warning network, 2008: national estimates of drug-related emergency department visits. Substance Abuse and Mental Health Services Administration, Rockville, MD; 2011
   Google Scholar
• Strain EC, Harrison JA, Bigelow GE. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. Clin Pharmacol Ther 2011;89:443-9
   PubMed Web of Science ®Google Scholar
• Middleton LS, Nuzzo PA, Loftwall MR, The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction 2011;106:1460-73
   PubMed Web of Science ®Google Scholar
• Heit HA, Gourlay DL. Buprenorphine - new tricks with an old molecule for pain management. Clin J Pain 2008;24:93-7
   PubMed Web of Science ®Google Scholar
• Florian J, Garnett CE, Nallani SC, A modeling and simulation approach to characterize methadone QT prolongation using pooled data from five clinical trials in MMT patients. Clin Pharmacol Ther 2012;91:666-72
   PubMed Web of Science ®Google Scholar
• Bruce RD, Altice FL, Gourevitch MN, Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr 2006;41:563-72
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 2010;19:4-16
   PubMed Web of Science ®Google Scholar
• Sullivan HR, Due SL. Urinary metabolites of d,l-methadone in maintenance subjects. J Med Chem 1973;16:909-13
   PubMed Web of Science ®Google Scholar
• Iribarne C, Berthou F, Baird S, Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996;9:365-73
   PubMed Web of Science ®Google Scholar
• Moody DE, Alburges ME, Parker RJ, The involvement of cytochrome P450 3A in the N-demethylation of l-α-acetylmethadol (LAAM), norLAAM and methadone. Drug Metab Dispos 1997;25:1347-53
   PubMed Web of Science ®Google Scholar
• Foster DJR, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 1999;47:403-12
   PubMed Web of Science ®Google Scholar
• Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos 2003;31:742-7
   PubMed Web of Science ®Google Scholar
• Prost F, Thormann W. Capillary electrophoresis to assess drug metabolism induced in vitro using single CYP450 enzymes (Supersomes™): Application to the chiral metabolism of mephenytoin and methadone. Electrophoresis 2003;24:2577-87
   PubMed Web of Science ®Google Scholar
• Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 2004;16:36-44
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Hoffer C, Whittington D, Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004;76:250-69
   PubMed Web of Science ®Google Scholar
• Foster DJR, Somogyi AA, Dyer KR, Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol 2000;50:427-40
   PubMed Web of Science ®Google Scholar
• Moody DE, Lin SN, Chang Y, An enantiomer selective liquid chromatography-tandem mass spectrometry method for methadone and EDDP validated for use in human plasma, urine and liver microsomes. J Anal Toxicol 2008;32:208-19
   PubMed Web of Science ®Google Scholar
• Totah RA, Sheffels P, Roberts T, Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008;108:363-74
   PubMed Web of Science ®Google Scholar
• Chang Y, Fang WB, Lin SN, Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic Clin Pharmacol Toxicol 2011;108:55-62
   PubMed Web of Science ®Google Scholar
• Oda Y, Kharasch ED. Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther 2001;298:1021-32
   PubMed Web of Science ®Google Scholar
• Crettol S, Digon P, Golay KP, In vitro P-glycoprotein-mediated transport of (R)-, (S)-, (R, S)-methadone, LAAM and their main metabolites. Pharmacology 2007;80:304-11
   PubMed Web of Science ®Google Scholar
• Hassan HE, Myers AL, Coop A, Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation. J Pharm Sci 2009;98:4928-40
   PubMed Web of Science ®Google Scholar
• Tournier N, Chevillard L, Megarbane B, Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol 2010;13:905-15
   PubMed Web of Science ®Google Scholar
• Shinderman M, Maxwell S, Brawand-Amey M, Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Depend 2003;69:205-11
   PubMed Web of Science ®Google Scholar
• Crettol S, Deglon JJ, Besson J, ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006;80:668-81
   PubMed Web of Science ®Google Scholar
• Shiran MR, Lennard MS, Iqbal MZ, Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol 2009;67:29-37
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Sim SC, Gomez A, Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116:496-526
   PubMed Web of Science ®Google Scholar
• Crettol S, Petrovic N, Murray M. Pharmacogenetics of phase I and phase II drug metabolism. Curr Pharm Des 2010;16:204-19
   PubMed Web of Science ®Google Scholar
• Chen CH, Wang SC, Tsou HH, Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients. Pharmacogenomics 2011;12:1397-406
   PubMed Web of Science ®Google Scholar
• Crettol S, Deglon JJ, Besson J, Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005;78:593-604
   PubMed Web of Science ®Google Scholar
• Wang SC, Ho IK, Tsou HH, CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer. J Clin Psychopharmacol 2011;31:463-9
   PubMed Web of Science ®Google Scholar
• Hung CC, Chiou MH, Huang BH, Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics 2011;12:1525-33
   PubMed Web of Science ®Google Scholar
• Fonseca F, de la Torre R, Diaz L, Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. PLoS One 2011;6:e19527
   PubMed Web of Science ®Google Scholar
• Levran O, Peles E, Hamon S, CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol 2011
   PubMed Web of Science ®Google Scholar
• Eap CB, Broly F, Mino A, Cytochrome P450 2D6 genotype and methadone steady-state concentrations. J Clin Psychopharmacol 2001;21:229-34
   PubMed Web of Science ®Google Scholar
• de los Cobos JP, Sinol N, Trujols J, Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment. Drug Alcohol Depend 2007;89:190-4
   PubMed Web of Science ®Google Scholar
• Tian JN, Ho IK, Tsou HH, UGT2B7 genetic polymorphisms are associated with the withdrawal symptoms in methadone maintenance patients. Pharmacogenomics 2012;13:879-88
   PubMed Web of Science ®Google Scholar
• Ieiri I. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab Pharmacokinet 2012;27:85-105
   PubMed Web of Science ®Google Scholar
• Coller JK, Barratt DT, Dahlen K, ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 2006;80:682-90
   PubMed Web of Science ®Google Scholar
• Levran O, O'Hara K, Peles E, ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 2008;17:2219-27
   PubMed Web of Science ®Google Scholar
• Cone EJ, Gorodetzky CW, Yousefnejad D, The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 1984;12:577-81
   PubMed Web of Science ®Google Scholar
• Iribarne C, Picart D, Dreano Y, Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci 1997;60:1953-64
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Yamamoto T, Chiba K, Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 1998;26:818-21
   PubMed Web of Science ®Google Scholar
• Moody DE, Slawson MH, Strain EC, A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a co-formulant, naloxone, that is suitable for in vivo and in vitro metabolism studies. Anal Biochem 2002;306:31-9
   PubMed Web of Science ®Google Scholar
• Picard N, Cresteil T, Djebli N, In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos 2005;33:689-95
   PubMed Web of Science ®Google Scholar
• Chang Y, Moody DE, McCance-Katz EF. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab Dispos 2006;34:440-8
   PubMed Web of Science ®Google Scholar
• Moody DE, Chang Y, Huang W, The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism. Basic Clin Pharmacol Toxicol 2009;105:211-15
   PubMed Web of Science ®Google Scholar
• Moody DE, Fang WB, Lin SN, Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes. Drug Metab Dispos 2009;37:2323-9
   PubMed Web of Science ®Google Scholar
• Chang Y, Moody DE. Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDP-glucuronosyltransferases. Drug Metab Lett 2009;3:101-7
   PubMedGoogle Scholar
• Rouguieg K, Picard N, Sauvage FL, Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes. Drug Metab Dispos 2010;38:40-5
   PubMed Web of Science ®Google Scholar
• Huang W, Moody DE, McCance-Katz EF. The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionization-tandem mass spectrometry. Ther Drug Monit 2006;28:245-51
   PubMed Web of Science ®Google Scholar
• McMillin GA, Davis R, Carlisle H, Patterns of free (unconjugated) buprenorphine, norbuprenorphine, and their glucuronides in urine using liquid chromatography-tandem mass spectrometry. J Anal Toxicol 2012;36:81-7
   PubMed Web of Science ®Google Scholar
• Brown SM, Campbell SD, Crafford A, P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception. J Pharmacol Exp Ther 2012;343:53-61
   PubMed Web of Science ®Google Scholar
• Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology 2010;112:226-38
   PubMed Web of Science ®Google Scholar
• Sanguinetti MC, Mitcheson JS. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 2005;26:119-24
   PubMed Web of Science ®Google Scholar
• Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology 2011;115:1363-81
   PubMed Web of Science ®Google Scholar
• Traynor J. mu-Opioid receptors and regulators of G protein signaling (RGS) proteins: from a symposium on new concepts in mu-opioid pharmacology. Drug Alcohol Depend 2012;121:173-80
   PubMed Web of Science ®Google Scholar
• Kristensen K, Christensen CB, Christrup LL. The mu1, mu2, delta, kappa opioid receptor binding properties of methadone stereoisomers and morphine. Life Sci 1995;56:45-50
   PubMed Web of Science ®Google Scholar
• Huang P, Kehner GB, Cowan A, Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 2001;297:688-95
   PubMed Web of Science ®Google Scholar
• Brown SM, Holtzman M, Kim T, Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active. Anesthesiology 2011;115:1251-60
   PubMed Web of Science ®Google Scholar
• Pert CB, Snyder SH. Opiate receptor: demonstration in nervous tissue. Science 1973;179:1011-14
   PubMed Web of Science ®Google Scholar
• Horng JS, Smits SE, Wong DT. The binding of optical isomers of methadone, α-acetylmethadol and their N-demethylated derivatives to the opiate receptors of rat brain. Res Commun Chem Pathol Pharmacol 1976;14:621-9
   PubMedGoogle Scholar
• Lotsch J, Skarke C, Wieting J, Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther 2006;79:72-89
   PubMed Web of Science ®Google Scholar
• Selley DE, Liu Q, Childers SR. Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus. J Pharmacol Exp Ther 1998;285:496-505
   PubMed Web of Science ®Google Scholar
• McPherson J, Rivero G, Baptist M, mu-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol 2010;78:756-66
   PubMed Web of Science ®Google Scholar
• Scott CC, Robbins EB, Chen KK. Pharmacological comparison of the optical isomers of methadon. J Pharmacol Exp Ther 1948;92:282-6
   Google Scholar
• Pohland A, Boaz HE, Sullivan HR. Synthesis and identification of metabolites resulting from the biotransformation of dl-methadone in man and in the rat. J Med Chem 1971;14:194-7
   PubMed Web of Science ®Google Scholar
• Sullivan HR, Smitz SE, Due SL, Metabolism of d-methadone: isolation and identification of analgesically active metabolites. Life Sci 1972;11:1093-104
   Google Scholar
• Ohtani M, Kotaki H, Sawada Y, Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1995;272:505-10
   PubMed Web of Science ®Google Scholar
• Holm KM, Linnet K. Chiral analysis of methadone and its main metabolite, EDDP, in postmortem brain and blood by automated SPE and liquid chromatography-mass spectrometry. J Anal Toxicol 2012;36:487-96
   PubMed Web of Science ®Google Scholar
• Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol 1998;22:430-4
   PubMed Web of Science ®Google Scholar
• Liu SJ, Roerig DL, Wang RI. Brain and plasma levels of methadone and their relationships to analgesic activity of methadone in rats. Drug Metab Dispos 1983;11:335-8
   PubMed Web of Science ®Google Scholar
• Garrido MJ, Valle M, Calvo R, Altered plasma and brain disposition and pharmacodynamics of methadone in abstinent rats. J Pharmacol Exp Ther 1999;288:179-87
   PubMed Web of Science ®Google Scholar
• Bauer B, Yang XD, Hartz AMS, In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Mol Pharmacol 2006;70:1212-19
   PubMed Web of Science ®Google Scholar
• Kalvass JC, Maurer TS, Pollack GM. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metab Dispos 2007;35:660-6
   PubMed Web of Science ®Google Scholar
• Foster DJ, Upton RN, Somogyi AA, The acute disposition of (R)- and (s)-methadone in brain and lung of sheep. J Pharmacokinet Pharmacodyn 2005;32:547-70
   PubMed Web of Science ®Google Scholar
• Jensen ML, Foster D, Upton R, Comparison of cerebral pharmacokinetics of buprenorphine and norbuprenorphine in an in vivo sheep model. Xenobiotica 2007;37:441-57
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Ortega I, Soengas I, Effect of P-glycoprotein inhibition on methadone analgesia and brain distribution in the rat. J Pharm Pharmacol 2004;56:367-74
   PubMed Web of Science ®Google Scholar
• Wang JS, Ruan Y, Taylor RM, Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacolgy 2004;173:132-8
   PubMed Web of Science ®Google Scholar
• Tournier N, Decleves X, Saubamea B, Opioid transport by ATP-binding cassette (ABC) transporters at the blood-brain barrier: implications for neuropsychopharmacology. Curr Pharm Des 2011;17:2829-42
   PubMed Web of Science ®Google Scholar
• Bouer R, Barthe L, Philibert C, The roles of P-glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac. Fundam Clin Pharmacol 1999;13:494-500
   PubMed Web of Science ®Google Scholar
• Nanovskaya T, Nekhayeva I, Karunaratne N, Role of P-glycoprotein in transplacental transfer of methadone. Biochem Pharmacol 2005;69:1869-78
   PubMed Web of Science ®Google Scholar
• Nekhayeva IA, Nanovskaya TN, Hankins GDV, Role of human placental efflux transporter P-glycoprotein in the transfer of buprenorphine, levo-alpha-acetylmethadol, and paclitaxel. Am J Perinatol 2006;23:423-30
   PubMed Web of Science ®Google Scholar
• Thompson SJ, Koszdin K, Bernards CM. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 2000;92:1392-9
   PubMed Web of Science ®Google Scholar
• Dagenais C, Graff CL, Pollack GM. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol 2004;67:269-76
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Hoffer C, Whittington D. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone. Br J Clin Pharmacol 2004;57:600-10
   PubMed Web of Science ®Google Scholar
• Katchman AN, McGroary KA, Kilborn MJ, Influence of opioid agonists on cardiac human ether-a-go-go related gene K+ currents. J Pharmacol Exp Ther 2002;303:688-94
   PubMed Web of Science ®Google Scholar
• Wedam EF, Bigelow GE, Johnson RE, QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007;167:2469-75
   PubMed Web of Science ®Google Scholar
• Eap CB, Crettol S, Rougier JS, Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 2007;81:719-28
   PubMed Web of Science ®Google Scholar
• Lin C, Somberg T, Molnar J, The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiology 2009;113:59-65
   PubMed Web of Science ®Google Scholar
• Ansermot N, Albayrak O, Schlapfer J, Substitution of (R,S)-methadone by (R)-methadone - Impact on QTc interval. Ar1. Vocci FJ, Acri J, Elkashef A. Medication development for addictive disorders: the state of the science. Am J Psychiatry 2005;162:1432-40
   PubMedGoogle Scholar
• Altice FL, Kamarulzaman A, Soriano VV, Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet 2010;376:367-87
   PubMed Web of Science ®Google Scholar
• Baker J, Rainey PM, Moody DE, Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine and tenofovir. Am J Addict 2010;19:17-29
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Rainey PM, Smith P, Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine. Am J Addict 2006;15:23-34
   PubMed Web of Science ®Google Scholar
• Gruber VA, Rainey PM, Moody DE, Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir. Clin Infect Dis 2012;54:414-23
   PubMed Web of Science ®Google Scholar
• McCance-Katz EF, Moody DE, Prathikanti S, Rifampin, but nor rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug Alcohol Depend 2011;118:326-34
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Bedynek PS, Park S, Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clin Pharmacol Ther 2008;84:497-505
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Walker A, Whittington D, Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend 2009;101:158-68
   PubMed Web of Science ®Google Scholar
• Kirby BJ, Collier AC, Kharasch ED, Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir. Drug Metab Dispos 2011;39:2329-37
   PubMed Web of Science ®Google Scholar
• Anggard E, Gunne L-M, Holmstrand J, Disposition of methadone in methadone maintenance. Clin Pharmacol Ther 1975;17:258-66
   PubMed Web of Science ®Google Scholar
• Verebly K, Volavka J, Mule S, Methadone in man: Pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther 1975;18:180-90
   PubMed Web of Science ®Google Scholar
• Buchard A, Linnet K, Johansen SS, Postmortem blood concentrations of R- and S-enantiomers of methadone and EDDP in drug users: influence of co-medication and P-glycoprotein genotype. J Forensic Sci 2010;55:457-63
   PubMed Web of Science ®Google Scholar
• Barrett DH, Luk AJ, Parrish RG, An investigation of Medical Examiner cases in which methadone was detected, Harris county, Texas, 1987-1992. J Forensic Sci 1996;41:442-8
   PubMed Web of Science ®Google Scholar
• Jones AW, Holmgren A, Ahlner J. Blood methadone concentrations in living and deceased persons: variations over time, subject deographics, and relevance of coingested drugs. J Anal Toxicol 2012;36:12-18
   PubMed Web of Science ®Google Scholar
• Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int 2001;121:65-9
   PubMed Web of Science ®Google Scholar
• Lai SH, Yao YJ, Lo DST. A survey of buprenorphine related deaths in Singapore. Forensic Sci Int 2006;162:80-6
   PubMed Web of Science ®Google Scholar
• Pirnay S, Borron SW, Giudicelli CP, A critical review of the causes of death among postmortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 2004;99:978-88
   PubMed Web of Science ®Google Scholar
• Moody DE. Drug interactions with benzodiazepines: Epidemiologic correlates with other CNS depressants and in vitro correlates with inhibitors and inducers of cytochrome P450 3A4. In: Mozayani A, Raymon LP, editors. Handbook of drug interactions a clinical and forensic guide. 2nd edition. Humana Press, New York, NY; 2012. p. 25-116
   Google Scholar
• Lintzeris N, Nielsen S. Benzodiazepines, methadone and buprenorphine: interactions and clinical management. Am J Addict 2010;19:59-72
   PubMed Web of Science ®Google Scholar
• Chang Y, Moody DE. Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes. Eur J Clin Pharmacol 2005;60:875-81
   PubMed Web of Science ®Google Scholar
• Pirnay S, Megarbane B, Decleves X, Buprenorphine alters desmethylflunitrazepam disposition and flunitrazepam toxicity in rats. Toxicol Sci 2008;106:64-73
   PubMed Web of Science ®Google Scholar
• Jung BF, Reidenberg MM. Interpretation of opioid levels: comparison of levels during chronic pain therapy to levels from forensic autopsies. Clin Pharmacol Ther 2005;77:324-34
   PubMed Web of Science ®Google Scholar
• Pelkonen O, Turpeinen M, Hakkola J, Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008;82:667-715
   PubMed Web of Science ®Google Scholar
• Wong SH, Wagner MA, Jentzen JM, Pharmacogenomics as an aspect of molecular autopsy for forensic pathology/toxicology: does genotyping CYP 2D6 serve as an adjunct for certifying methadone toxicity. J Forensic Sci 2003;48:1406-15
   PubMed Web of Science ®Google Scholar
• Bunten H, Liang WJ, Seneviratne C, OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clin Pharmacol Ther 2010;88:383-9
   PubMed Web of Science ®Google Scholar
• Bunten H, Liang WJ, Pounder DJ, Interindividual variability in the prevalence of OPRM1 and CYP2B6 gene variations may identify drug-susceptible populations. J Anal Toxicol 2011;35:431-7
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Hoffer C, Whittington D, Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport. Anesthesiology 2009;110:660-72
   PubMed Web of Science ®Google Scholar
• Rubenstein RB, Kreek MJ, Mbawa N, Human spinal fluid methadone levels. Drug Alcohol Depend 1978;3:103-6
   PubMed Web of Science ®Google Scholar
• Henriksen G, Willoch F. Imaging of opioid receptors in the central nervous system. Brain 2008;131:1171-96
   PubMed Web of Science ®Google Scholar
• Greenwald MK, Johanson CE, Moody DE, Effects of buprenorphine maintenance dose on µ-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 2003;28:2000-9
   PubMed Web of Science ®Google Scholar
• Greenwald M, Johanson CE, Bueller J, Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiat 2007;61:101-10
   PubMed Web of Science ®Google Scholar
• Melichar JK, Hume SP, Williams TM, Using [11C]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: clinical and preclinical studies. J Pharmacol Exp Ther 2005;312:309-15
   PubMed Web of Science ®Google Scholar
• Kling MA, Carson RE, Borg L, Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther 2000;295:1070-6
   PubMed Web of Science ®Google Scholar
• Wilhelm I, Fazakas C, Krizbai IA. In vitro models of the blood-brain barrier. Acta Neurobiol Exp (Wars) 2011;71:113-28
   PubMed Web of Science ®Google Scholar
• Benedek IH, Jobes J, Xiang Q, Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. Drug Des Devel Ther 2011;5:455-63
   PubMed Web of Science ®Google Scholar
• Neff JA, Moody DE. Differential N-demethylation of l-a-acetylmethadol (LAAM) and norLAAM by cytochrome P450s 2B6, 2C18, and 3A4. Biochem Biophys Res Commun 2001;284:751-6
   PubMed Web of Science ®Google Scholar